The metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes
conference contribution
posted on 2020-05-13, 13:32 authored by R Herring, F Shojaee-Moradie, R Garesse, M Stevenage, N Jackson, C Lucy, BA Fielding, A Umpleby, DL Russell-Jones, M DaviesThe metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes
History
Citation
Diabetologia, 2019, 62 (Suppl 1), pp. S124-S124 (1)Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Diabetes Research CentreSource
55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Barcelona, SPAINPublished in
DiabetologiaVolume
62Issue
Suppl 1Pagination
S124-S124 (1)Publisher
SPRINGERissn
0012-186Xeissn
1432-0428Copyright date
2020Available date
2020-08-05Publisher DOI
Publisher version
https://link.springer.com/article/10.1007/s00125-019-4946-6Spatial coverage
Barcelona, SpainTemporal coverage: start date
2019-09-16Temporal coverage: end date
2019-09-20Language
enAdministrator link
Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC